Hookipa Pharma (NASDAQ:HOOK) Cut to Sector Perform at Royal Bank of Canada

Royal Bank of Canada downgraded shares of Hookipa Pharma (NASDAQ:HOOK) from an outperform rating to a sector perform rating in a report published on Friday, MarketBeat Ratings reports. They currently have $2.00 price objective on the stock, down from their prior price objective of $48.00.

Separately, JMP Securities dropped their price target on shares of Hookipa Pharma from $24.00 to $7.00 and set a “market outperform” rating on the stock in a research report on Thursday, November 21st.

Hookipa Pharma Trading Down 5.6 %

Hookipa Pharma stock opened at $2.02 on Friday. Hookipa Pharma has a 1-year low of $1.88 and a 1-year high of $11.30. The firm’s fifty day simple moving average is $3.06 and its 200-day simple moving average is $4.64. The company has a market capitalization of $24.35 million, a P/E ratio of -0.54 and a beta of 0.71.

Institutional Inflows and Outflows

A number of large investors have recently modified their holdings of HOOK. Renaissance Technologies LLC boosted its position in shares of Hookipa Pharma by 38.4% during the 2nd quarter. Renaissance Technologies LLC now owns 302,246 shares of the company’s stock valued at $179,000 after acquiring an additional 83,800 shares in the last quarter. Ikarian Capital LLC acquired a new stake in Hookipa Pharma during the third quarter valued at approximately $228,000. Finally, Acadian Asset Management LLC boosted its holdings in Hookipa Pharma by 12.3% during the second quarter. Acadian Asset Management LLC now owns 991,106 shares of the company’s stock valued at $586,000 after purchasing an additional 108,844 shares in the last quarter. 63.88% of the stock is currently owned by institutional investors and hedge funds.

About Hookipa Pharma

HOOKIPA Pharma Inc, a clinical-stage biopharmaceutical company, develops immunotherapeutics targeting infectious diseases and cancers based on its proprietary arenavirus platform. The company's lead infectious disease product candidate is HB-101, which is in a randomized double-blinded Phase 2 clinical trial in cytomegalovirus-negative patients awaiting kidney transplantation from cytomegalovirus-positive donors.